RxDoctor Payments Data

Fatima Samad, MD

Cardiovascular Disease · Columbia, MONPI 1447566849

Payments from drug & device makers

$1,721in general payments, 2019–2025

Across 32 payments — averaging $53.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$938
  • Abbott$281
  • E.r. Squibb & Sons, L.L.C.$177
  • Amgen$77
  • Pfizer$71
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
  • plus $141 from 7 others

What the payments were for

  • Travel & lodging$92254%
  • Food & beverage$79946%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,721 in reported general payments places this provider in the 45th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$45,268
Medicare patients
630
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban245$355,043
XareltoRivaroxaban61$90,471
FarxigaDapagliflozin Propanediol39$41,455
EntrestoSacubitril/Valsartan15$28,317
Repatha SureclickEvolocumab21$16,429
Metoprolol Succinate261$2,619
Atorvastatin Calcium208$2,011
Ezetimibe182$1,727
Carvedilol168$1,151
Amiodarone Hcl34$1,131
Rosuvastatin Calcium106$1,075
ClopidogrelClopidogrel Bisulfate89$1,021
Flecainide Acetate14$900
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$892
Isosorbide Mononitrate ErIsosorbide Mononitrate90$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$355,043245 claims
Johnson & JohnsonXarelto$35$90,47161 claims
NovartisEntresto$17$28,31715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →